Ultrasound-Guided Continuous Thoracic Paravertebral Infusion of Methylene Blue in the Treatment of Postherpetic Neuralgia: A Prospective, Randomized, Controlled Study (2021)

Peer-Reviewed Study · Wang M, Zhang J, Zheng L, et al. · April 11, 2021

Wang M et al., 2021-04-11: Randomized trial of continuous thoracic paravertebral infusion of 0.2% methylene blue plus lidocaine for postherpetic neuralgia, finding better pain, sleep and mood scores than lidocaine alone over six months.

Compared with the control group, the MB group had significantly reduced NRS scores, ISI scores, PHQ-9 scores, and rescue medication dosages at each observation time point.

Wang M et al., 2021-04-11: Randomized trial of continuous thoracic paravertebral infusion of 0.2% methylene blue plus lidocaine for postherpetic neuralgia, finding better pain, sleep and mood scores than lidocaine alone over six months. Study type: prospective randomized controlled trial. N=104. Country: China. MB 0.2% in 300 mL with 5% lidocaine, continuous paravertebral infusion; 6-month follow-up. Funding: National Natural Science Foundation of China. Conflicts: not stated. Comparator: 5% lidocaine alone. This is a nerve-block use, not systemic therapy. Study type: randomized trial.